CL2022002243A1 - Inhibidores y usos de los mismos - Google Patents

Inhibidores y usos de los mismos

Info

Publication number
CL2022002243A1
CL2022002243A1 CL2022002243A CL2022002243A CL2022002243A1 CL 2022002243 A1 CL2022002243 A1 CL 2022002243A1 CL 2022002243 A CL2022002243 A CL 2022002243A CL 2022002243 A CL2022002243 A CL 2022002243A CL 2022002243 A1 CL2022002243 A1 CL 2022002243A1
Authority
CL
Chile
Prior art keywords
inhibitors
receptors
relates
igfbp5
antigen
Prior art date
Application number
CL2022002243A
Other languages
English (en)
Inventor
Amabile Giovanni
Original Assignee
Enthera S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enthera S R L filed Critical Enthera S R L
Publication of CL2022002243A1 publication Critical patent/CL2022002243A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a inhibidores de la IGFBP5 y/o de al menos uno de sus receptores, en donde dicho inhibidor tiene efecto antifibrótico, métodos para su producción, composiciones farmacéuticas que contienen dichos inhibidores y usos de los mismos. En particular, la invención se refiere a anticuerpos o fragmentos de unión a antígeno de los mismos que se unen específicamente a IGFBP5 humano y/o a al menos uno de sus receptores.
CL2022002243A 2020-02-20 2022-08-17 Inhibidores y usos de los mismos CL2022002243A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20158553.6A EP3868396A1 (en) 2020-02-20 2020-02-20 Inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CL2022002243A1 true CL2022002243A1 (es) 2023-03-10

Family

ID=69804431

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002243A CL2022002243A1 (es) 2020-02-20 2022-08-17 Inhibidores y usos de los mismos

Country Status (12)

Country Link
US (1) US20230192827A1 (es)
EP (2) EP3868396A1 (es)
JP (1) JP2023514254A (es)
KR (1) KR20220143865A (es)
CN (1) CN115052623A (es)
AU (1) AU2021225061A1 (es)
BR (1) BR112022015473A2 (es)
CA (1) CA3162043A1 (es)
CL (1) CL2022002243A1 (es)
IL (1) IL294941A (es)
MX (1) MX2022009525A (es)
WO (1) WO2021165499A1 (es)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
DE69830315T2 (de) 1997-06-24 2006-02-02 Genentech Inc., San Francisco Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
ES2284247T3 (es) 1998-04-03 2007-11-01 University Of Iowa Research Foundation Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos.
ATE458007T1 (de) 1998-04-20 2010-03-15 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
WO2002020565A2 (en) 2000-09-08 2002-03-14 Universität Zürich Collections of repeat proteins comprising repeat modules
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
CA2838062C (en) 2001-08-03 2015-12-22 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2005044859A2 (en) 2003-11-05 2005-05-19 Glycart Biotechnology Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
WO2006034488A2 (en) 2004-09-23 2006-03-30 Genentech, Inc. Cysteine engineered antibodies and conjugates
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method

Also Published As

Publication number Publication date
MX2022009525A (es) 2022-09-09
IL294941A (en) 2022-09-01
CA3162043A1 (en) 2021-08-26
CN115052623A (zh) 2022-09-13
EP3868396A1 (en) 2021-08-25
AU2021225061A1 (en) 2022-07-21
WO2021165499A1 (en) 2021-08-26
US20230192827A1 (en) 2023-06-22
KR20220143865A (ko) 2022-10-25
EP4106804A1 (en) 2022-12-28
BR112022015473A2 (pt) 2022-10-11
JP2023514254A (ja) 2023-04-05

Similar Documents

Publication Publication Date Title
CY1125065T1 (el) Αναστολεις mcl-1
CO2017013356A2 (es) Anticuerpos de factor xi
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
BR112019001206A2 (pt) anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
CL2019001740A1 (es) Novedoso conjugado de amanitina.
CL2018002998A1 (es) Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
BR112017016636A2 (pt) formulação líquida estável para anticorpos monoclonais
CL2019000508A1 (es) Formulaciones, kits y métodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados.
CR20190105A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
BR112017006468A2 (pt) anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
CO2021002954A2 (es) Anticuerpos anti-αvβ8 y composiciones y usos de los mismos
CO2019006073A2 (es) Estructura cristalina de gremlina 1 y anticuerpo inhibidor
NI202000050A (es) Anticuerpos de cadena pesada que se unen a cd22
AR119746A1 (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos
BR112022008365A2 (pt) Inibidores de cd73
EA201992027A1 (ru) Водный состав антитела против pd-l1
CO2023017156A2 (es) Anticuerpos anti-sirp-alfa
CL2022002243A1 (es) Inhibidores y usos de los mismos
CL2023000216A1 (es) Anticuerpos anti-abeta
ECSP22021881A (es) Composición farmacéutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso
BR112018006900A2 (pt) anticorpo ou um seu fragmento antígeno-ligante que especificamente se liga a erbb3, composição farmacêutica, e método para a prevenção ou tratamento de uma doença relacionada com a ativação ou a superexpressão da proteína erbb3 em um indivíduo